The zinc file
Thymulin, zinc and Lazarus Research Peptides
The peptide's activity depends on its metal partner. Its most ambitious lung result depends on an engineered delivery system. Both conditions deserve a place in the story.
Thymulin and serum thymic factor
Thymulin is made exclusively by thymic epithelial cells. Older papers call it serum thymic factor, or FTS. Its nine-amino-acid sequence is pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, and biological activity requires zinc bound in a 1:1 ratio. The zinc-bound form takes on a particular three-dimensional conformation detectable by NMR. Without zinc, the apopeptide is inactive.
I understand thymulin more clearly through that dependency than through the broad phrase immune hormone. It gives a concrete reason why a peptide can be present while the measured activity is low. The same review describes activity falling during zinc deficiency and being corrected by zinc supplementation in animals and humans. That finding makes zinc status central to interpreting the assay. It supplies no general instruction to supplement or administer thymulin.
Reversing established lung pathology in mice
The 2020 experimental asthma study is the boldest restoration result in this file. Allergic asthma was fully and stably established in mice before researchers gave a single intratracheal dose of thymulin-expressing plasmids carried in mucus-penetrating nanoparticles. At 20 days, the reported normalization covered chronic inflammation, pulmonary fibrosis and mechanical dysregulation.
I rate the breadth highly: lung mechanics were assessed alongside inflammatory measurements. The intervention's identity deserves equal attention: genetic instructions, a carrier designed to cross mucus, and delivery into the mouse airway. A bottle bearing the peptide's name cannot inherit that whole experiment.
Duration and a comparable delivery strategy in people are the unresolved questions for translation. The cited result establishes reversal in this experimental mouse model; it leaves those human questions open.
Thymus, pituitary and inflammation
Thymulin also participates in communication between the thymus and the neuroendocrine system. The 2009 review of this two-way axis describes regulation of thymulin secretion and its effects on the pituitary, along with anti-inflammatory and analgesic work in rat brain. The gland's output has a conversation with the systems regulating it.
A 2014 physiology review describes a synthetic active analog, metFTS, placed into adenoviral vectors. In congenitally athymic mice, this approach restored circulating thymulin and prevented hormonal and reproductive abnormalities associated with thymodeficiency. That is a different restoration experiment again: an analog expressed through gene delivery in animals missing a thymus.
The LPS inflammation experiment in male BALB/c mice examined pretreatment before an inflammatory challenge. Thymulin reduced inflammatory cytokines and inducible heat-shock proteins and modulated NF-kB and JNK signalling. Its timing distinguishes it from the established-asthma study. The three verbs matter to me: prevent, replace, reverse. A run of anti-inflammatory outcomes can blur those differences.
Human evidence and thymulin identity
The human literature is sparse and dated; some studies used synthetic analogs rather than native thymulin. The evidence gathered here cannot establish a modern human treatment, a standardized dose or validated human pharmacokinetics. Thymulin has no FDA approval for any indication. It is handled as a research chemical for laboratory use only.
Names create another problem. Thymulin, thymosin alpha-1 and thymalin are chemically distinct. A search for a thymulin COA or a thymulin TFA salt link does not resolve whether the material matches the zinc-bound complex described in the biochemical review. This site has no batch-testing data or product certificate to inspect, so I cannot authenticate a preparation. The FAQ addresses those searches without treating a catalogue name as evidence of biological activity.